Sana Biotechnology Reports $63.6 Million Net Loss in Q2 2026, Decreased from $93.8 Million Last Year

Sana Biotechnology, Inc. reported a net loss of $63.6 million for the second quarter of 2026, a decrease from a net loss of $93.8 million in the same period last year. For the first half of 2026, the company recorded a net loss of $110.8 million, down from $143.2 million in the first half of 2025. The reduction in losses is attributed to a significant decrease in total operating expenses, which fell to $65.4 million in Q2 2026 from $95.0 million in Q2 2025, primarily due to the absence of impairment charges that were recorded in the previous year.

Sana's total operating expenses for the first half of 2026 were $114.0 million, compared to $145.6 million in the same period of 2025. The decrease was driven by lower research and development costs, which amounted to $59.4 million in the first half of 2026, down from $67.0 million in 2025. The company reported an increase in research and development related success payments and contingent consideration, which rose to $32.3 million in the first half of 2026 from $12.2 million in the prior year, reflecting changes in the estimated fair value of contingent liabilities.

In terms of strategic developments, Sana Biotechnology entered into a stock purchase agreement with Mayo Clinic in April 2026, resulting in gross proceeds of approximately $25 million from the sale of 7.5 million shares. The company may also receive an additional $25 million if Mayo Clinic opts to purchase more shares by August 31, 2026. Additionally, Sana sold 21.6 million shares under an at-the-market equity offering, generating net proceeds of $68.6 million during the second quarter. These funds are intended to support the development of its product candidates, including SC451, a therapy for type 1 diabetes.

As of June 30, 2026, Sana reported cash, cash equivalents, and marketable securities totaling $160.5 million. The company has indicated that its current capital resources may not be sufficient to fund operations for at least the next year, raising concerns about its ability to continue as a going concern. Sana plans to address this through potential equity or debt offerings and strategic collaborations. The company has not yet generated revenue from product sales and continues to rely on external financing to support its research and development efforts.

Looking ahead, Sana Biotechnology is focused on advancing its product candidates, including SC451 for type 1 diabetes and two in vivo CAR T cell therapies, SG293 and SG227, targeting various cancers. The company is preparing for clinical trials and aims to file investigational new drug applications for its therapies in the near future. However, the success of these initiatives is contingent on securing additional funding and navigating the complexities of clinical development and regulatory approval processes.